Chronic skin diseases have a huge impact on patients’ lives. We can help make great improvements in our patients’ lives, if they will use the medicine we prescribe. That’s a big if. Dr. Steven Feldman has opened our understanding of adherence issues in the treatment of psoriasis, atopic dermatitis and acne. He is author of over 700 MEDLINE-referenced publications and serves as editor of the Journal of Dermatological Treatment.
Dr. Feldman is a board-certified dermatologist and dermatopathologist. He is professor of dermatology, pathology and public health sciences at the Wake Forest University School of Medicine in North Carolina. He earned his M.D. and PhD degrees from Duke University in Durham, NC, and then completed a dermatology residency at the University of North Carolina at Chapel Hill and his dermatopathology residency at the Medical University of South Carolina, in Charleston.
Adherence to Treatment
- Describe typical patterns of how patients use their medications
- List interventions to improve patients' adherence behavior
- New advances in dermatologic treatment
- Development of new technology
- Advances in medical knowledge
- Bolognia, Jorizzo, Shafer. Dermatology textbook by Elsevier.
- Osterberg L, Blaschke T. Adherence to Medication. N Engl J Med. Aug 2005; 353:487-497.
- Horwitz RI, Horwitz SM. Adherence to Treatment and Health Outcomes. Arch Intern Med. 1993 Aug 23; 153(16): 1863-8.
Core Competencies: 2, 3, 4, 6
Disclosures: Speaker for: Abbvie, Galderma, Janssen, Leo Pharma, Novartis, Stiefel/GSK, Taro
Consultant for: Abbvie, Advance Medical, Amgen, Baxter, Caremark, Celgene, Cosmederm, Informa, Galderma, Gerson Lehrman Group, GSK, Guidepoint Global, Hanall Pharmaceutical Co, Ltd, Kikaku, Leo Pharma, Lilly, Merck & Co, Inc., Merz Pharmaceuticals, Mylan, Novartis, Pfizer Inc., Qurient, Stiefel/GSK, Suncare Research, Xenoport
Grant Support from: Abbvie Amgen, Anacor Pharmaceuticals, Celgene, Galderma, Janssen, Novartis, Pfizer Inc, Stiefel/GSK
Advisory Board for: Boehringer Ingelheim, Pfizer Inc., Xenoport
Founder, Stockholder, CTO for: Causa Technologies
Stock (majority owner) for: Medical Quality Enhancement Corporation
Editor for: Informa
Royalties from: Informa Healthcare, UpToDate, Xlibris
Departmental Funding from: Acuderm, Advanced Tissue Sciences, Allergan, Aventis, Bristol-Myers Squibb, Combe, Curatek, Ferndale, Fujisawa, Hermal, Hoffman La Roche, Galderma, Genderm, Glaxo Wellcome, Hill, Janssen, Mayrand, Neo Strata, Neutrogena, Novartis, Oclassen, Ortho, Person & Covey, Proctor & Gamble, RJR Nabisco, Schering-Plough, Shelton, SmithKline, Stiefel, 3M, United Catalyst, Upjohn, Wolff Systems